Richardson P G, Hofmeister C C, Raje N S, Siegel D S, Lonial S, Laubach J, Efebera Y A, Vesole D H, Nooka A K, Rosenblatt J, Doss D, Zaki M H, Bensmaine A, Herring J, Li Y, Watkins L, Chen M S, Anderson K C
Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
Leukemia. 2018 Oct;32(10):2305. doi: 10.1038/s41375-018-0235-5.
Following the publication of this article, the authors noted that the pomalidomide dose for the additional SC cohort in Fig. 1 was incorrectly listed. The correct dose for pomalidomide in the additional SC cohort should be the maximum tolerated dose of 4 mg/day, not 2 mg/day as listed in the original Fig. 1. The authors apologize for any inconvenience caused.
在本文发表后，作者注意到图1中额外皮下注射队列的泊马度胺剂量列出有误。额外皮下注射队列中泊马度胺的正确剂量应为最大耐受剂量4毫克/天，而非原始图1中列出的2毫克/天。作者对由此造成的任何不便表示歉意。
